Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Canntab Therapeutics Ltd C.PILL

Alternate Symbol(s):  CTABF

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and... see more

Recent & Breaking News (CSE:PILL)

FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

Newsfile September 25, 2018

Canntab Added to CSE Composite Index

Newsfile September 24, 2018

Canntab Sets New All-Time High Trading Prices and Volume

Newsfile September 20, 2018

Canntab Exceeds All-Time High Trading Prices and Grants Options

Newsfile September 19, 2018

Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms

Newsfile September 18, 2018

Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

Newsfile September 18, 2018

Canntab Therapeutics Launches Capital Markets Communications Strategy

Newsfile September 11, 2018

Canntab Engages Industry Leader Lorne Gertner as Consultant

Canada NewsWire July 16, 2018

InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com

Newsfile July 11, 2018

Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

Canada NewsWire July 9, 2018

Canntab Announces Launch of Innovative Hemp Oil Capsules

Newsfile June 20, 2018

Canntab Announces Director Resignation

Newsfile June 14, 2018

Canntab: Advancing Cannabinoid Research in Australia -- CFN Media

GlobeNewswire June 6, 2018

CORRECTING and REPLACING – Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media

GlobeNewswire June 1, 2018

Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media

GlobeNewswire May 31, 2018

Canntab Therapeutics Files 2 New Canadian Patent Applications Related to Pharmaceutical Cannabis

Newsfile May 25, 2018

Canntab Appoints Bob Woloschuk to Advisory Board

Newsfile May 17, 2018

Canntab Provides Clarification on CFN Media Engagement

Newsfile May 15, 2018

Canntab Therapeutics Engages CFN Media to Build New Investor Audience

GlobeNewswire May 15, 2018

Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation

GlobeNewswire May 14, 2018